Recent studies highlight the potential of mRNA vaccine technology beyond COVID-19, specifically in cancer treatment. Researchers at Memorial Sloan Kettering Cancer Center are investigating mRNA vaccines targeting neoantigens in pancreatic tumors, aiming to enhance immune response against the disease. Meanwhile, a UK rugby player's death has sparked discussions about 'Turbo Cancer', a term used for aggressive cancers potentially linked to mRNA vaccines, though mainstream oncology remains skeptical. The DCVax-L vaccine, a personalized treatment for glioblastoma, has faced criticism for its methodology and failure to meet primary endpoints in clinical trials, prompting debates in neuro-oncology. Conversely, there are indications that mRNA vaccines may improve survival rates for some cancer patients undergoing immunotherapy. Additionally, a groundbreaking clinical trial for a new pancreatic cancer vaccine has begun in Europe, offering hope for more effective treatments for this deadly disease.